The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents.
Identifieur interne : 000474 ( Main/Exploration ); précédent : 000473; suivant : 000475The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents.
Auteurs : Anton De Spiegeleer [Belgique] ; Antoon Bronselaer [Belgique] ; James T. Teo [Royaume-Uni] ; Geert Byttebier [Belgique] ; Guy De Tré [Belgique] ; Luc Belmans [Belgique] ; Richard Dobson [Royaume-Uni] ; Evelien Wynendaele [Belgique] ; Christophe Van De Wiele [Belgique] ; Filip Vandaele [Belgique] ; Diemer Van Dijck [Belgique] ; Dan Bean [Royaume-Uni] ; David Fedson [France] ; Bart De Spiegeleer [Belgique]Source :
- Journal of the American Medical Directors Association [ 1538-9375 ] ; 2020.
Descripteurs français
- KwdFr :
- Antagonistes des récepteurs aux angiotensines (administration et posologie), Appréciation des risques (MeSH), Belgique (épidémiologie), Cause de décès (MeSH), Femelle (MeSH), Humains (MeSH), Indice de gravité de la maladie (MeSH), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (épidémiologie), Inhibiteurs de l'enzyme de conversion de l'angiotensine (administration et posologie), Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (administration et posologie), Maisons de repos (statistiques et données numériques), Maisons de retraite médicalisées (statistiques et données numériques), Modèles logistiques (MeSH), Mâle (MeSH), Odds ratio (MeSH), Pandémies (statistiques et données numériques), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (épidémiologie), Résultat thérapeutique (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Taux de survie (MeSH), Études de cohortes (MeSH), Études rétrospectives (MeSH), Évaluation gériatrique (MeSH).
- MESH :
- administration et posologie : Antagonistes des récepteurs aux angiotensines, Inhibiteurs de l'enzyme de conversion de l'angiotensine, Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase.
- statistiques et données numériques : Maisons de repos, Maisons de retraite médicalisées, Pandémies.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- épidémiologie : Belgique, Infections à coronavirus, Pneumopathie virale.
- Appréciation des risques, Cause de décès, Femelle, Humains, Indice de gravité de la maladie, Modèles logistiques, Mâle, Odds ratio, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Taux de survie, Études de cohortes, Études rétrospectives, Évaluation gériatrique.
- Wicri :
- geographic : Belgique.
English descriptors
- KwdEn :
- Aged (MeSH), Aged, 80 and over (MeSH), Angiotensin Receptor Antagonists (administration & dosage), Angiotensin-Converting Enzyme Inhibitors (administration & dosage), Belgium (epidemiology), Cause of Death (MeSH), Cohort Studies (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Female (MeSH), Geriatric Assessment (MeSH), Homes for the Aged (statistics & numerical data), Humans (MeSH), Hydroxymethylglutaryl-CoA Reductase Inhibitors (administration & dosage), Logistic Models (MeSH), Male (MeSH), Nursing Homes (statistics & numerical data), Odds Ratio (MeSH), Pandemics (statistics & numerical data), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Retrospective Studies (MeSH), Risk Assessment (MeSH), Severity of Illness Index (MeSH), Survival Rate (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , administration & dosage : Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Hydroxymethylglutaryl-CoA Reductase Inhibitors.
- geographic , epidemiology : Belgium.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- statistics & numerical data : Homes for the Aged, Nursing Homes, Pandemics.
- Aged, Aged, 80 and over, Cause of Death, Cohort Studies, Female, Geriatric Assessment, Humans, Logistic Models, Male, Odds Ratio, Retrospective Studies, Risk Assessment, Severity of Illness Index, Survival Rate, Treatment Outcome.
Abstract
OBJECTIVES
Angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARBs), and HMG-CoA reductase inhibitors ("statins") have been hypothesized to affect COVID-19 severity. However, up to now, no studies investigating this association have been conducted in the most vulnerable and affected population groups (ie, older adults residing in nursing homes). The objective of this study was to explore the association of ACEi/ARB and/or statins with clinical manifestations in COVID-19-infected older adults residing in nursing homes.
DESIGN
We undertook a retrospective multicenter cohort study to analyze the association between ACEi/ARB and/or statin use with clinical outcome of COVID-19. The outcomes were (1) serious COVID-19 defined as long-stay hospital admission or death within 14 days of disease onset, and (2) asymptomatic (ie, no disease symptoms in the whole study period while still being diagnosed by polymerase chain reaction).
SETTING AND PARTICIPANTS
A total of 154 COVID-19-positive subjects were identified, residing in 1 of 2 Belgian nursing homes that experienced similar COVID-19 outbreaks.
MEASURES
Logistic regression models were applied with age, sex, functional status, diabetes, and hypertension as covariates.
RESULTS
We found a statistically significant association between statin intake and the absence of symptoms during COVID-19 (odds ratio [OR] 2.91; confidence interval [CI] 1.27-6.71), which remained statistically significant after adjusting for covariates (OR 2.65; CI 1.13-6.68). Although the effects of statin intake on serious clinical outcome were in the same beneficial direction, these were not statistically significant (OR 0.75; CI 0.24-1.87). There was also no statistically significant association between ACEi/ARB and asymptomatic status (OR 2.72; CI 0.59-25.1) or serious clinical outcome (OR 0.48; CI 0.10-1.97).
CONCLUSIONS AND IMPLICATIONS
Our data indicate that statin intake in older, frail adults could be associated with a considerable beneficial effect on COVID-19 clinical symptoms. The role of statins and renin-angiotensin system drugs needs to be further explored in larger observational studies as well as randomized clinical trials.
DOI: 10.1016/j.jamda.2020.06.018
PubMed: 32674818
PubMed Central: PMC7294267
Affiliations:
- Belgique, France, Royaume-Uni
- Angleterre, Grand Londres, Province de Flandre-Orientale, Région flamande
- Gand, Londres
- Université de Gand
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents.</title><author><name sortKey="De Spiegeleer, Anton" sort="De Spiegeleer, Anton" uniqKey="De Spiegeleer A" first="Anton" last="De Spiegeleer">Anton De Spiegeleer</name><affiliation wicri:level="4"><nlm:affiliation>Drug Quality and Registration Group, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium; Department of Geriatrics, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB-Center for Inflammation Research, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Drug Quality and Registration Group, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium; Department of Geriatrics, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB-Center for Inflammation Research, Ghent</wicri:regionArea><orgName type="university">Université de Gand</orgName><placeName><settlement type="city">Gand</settlement><region>Région flamande</region><region type="district" nuts="2">Province de Flandre-Orientale</region></placeName></affiliation></author><author><name sortKey="Bronselaer, Antoon" sort="Bronselaer, Antoon" uniqKey="Bronselaer A" first="Antoon" last="Bronselaer">Antoon Bronselaer</name><affiliation wicri:level="4"><nlm:affiliation>DDCM Laboratory, Department of Telecommunications and Information Processing, Faculty of Engineering and Architecture, Ghent University, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>DDCM Laboratory, Department of Telecommunications and Information Processing, Faculty of Engineering and Architecture, Ghent University, Ghent</wicri:regionArea><orgName type="university">Université de Gand</orgName><placeName><settlement type="city">Gand</settlement><region>Région flamande</region><region type="district" nuts="2">Province de Flandre-Orientale</region></placeName></affiliation></author><author><name sortKey="Teo, James T" sort="Teo, James T" uniqKey="Teo J" first="James T" last="Teo">James T. Teo</name><affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Byttebier, Geert" sort="Byttebier, Geert" uniqKey="Byttebier G" first="Geert" last="Byttebier">Geert Byttebier</name><affiliation wicri:level="1"><nlm:affiliation>Bioconstat BV, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Bioconstat BV, Ghent</wicri:regionArea><wicri:noRegion>Ghent</wicri:noRegion></affiliation></author><author><name sortKey="De Tre, Guy" sort="De Tre, Guy" uniqKey="De Tre G" first="Guy" last="De Tré">Guy De Tré</name><affiliation wicri:level="4"><nlm:affiliation>DDCM Laboratory, Department of Telecommunications and Information Processing, Faculty of Engineering and Architecture, Ghent University, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>DDCM Laboratory, Department of Telecommunications and Information Processing, Faculty of Engineering and Architecture, Ghent University, Ghent</wicri:regionArea><orgName type="university">Université de Gand</orgName><placeName><settlement type="city">Gand</settlement><region>Région flamande</region><region type="district" nuts="2">Province de Flandre-Orientale</region></placeName></affiliation></author><author><name sortKey="Belmans, Luc" sort="Belmans, Luc" uniqKey="Belmans L" first="Luc" last="Belmans">Luc Belmans</name><affiliation wicri:level="1"><nlm:affiliation>Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent</wicri:regionArea><wicri:noRegion>Ghent</wicri:noRegion></affiliation></author><author><name sortKey="Dobson, Richard" sort="Dobson, Richard" uniqKey="Dobson R" first="Richard" last="Dobson">Richard Dobson</name><affiliation wicri:level="3"><nlm:affiliation>Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Wynendaele, Evelien" sort="Wynendaele, Evelien" uniqKey="Wynendaele E" first="Evelien" last="Wynendaele">Evelien Wynendaele</name><affiliation wicri:level="4"><nlm:affiliation>Drug Quality and Registration Group, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Drug Quality and Registration Group, Faculty of Pharmaceutical Sciences, Ghent University, Ghent</wicri:regionArea><orgName type="university">Université de Gand</orgName><placeName><settlement type="city">Gand</settlement><region>Région flamande</region><region type="district" nuts="2">Province de Flandre-Orientale</region></placeName></affiliation></author><author><name sortKey="Van De Wiele, Christophe" sort="Van De Wiele, Christophe" uniqKey="Van De Wiele C" first="Christophe" last="Van De Wiele">Christophe Van De Wiele</name><affiliation wicri:level="1"><nlm:affiliation>Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent</wicri:regionArea><wicri:noRegion>Ghent</wicri:noRegion></affiliation></author><author><name sortKey="Vandaele, Filip" sort="Vandaele, Filip" uniqKey="Vandaele F" first="Filip" last="Vandaele">Filip Vandaele</name><affiliation wicri:level="1"><nlm:affiliation>VZW Zorg-Saam Zusters Kindsheid Jesu, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>VZW Zorg-Saam Zusters Kindsheid Jesu, Ghent</wicri:regionArea><wicri:noRegion>Ghent</wicri:noRegion></affiliation></author><author><name sortKey="Van Dijck, Diemer" sort="Van Dijck, Diemer" uniqKey="Van Dijck D" first="Diemer" last="Van Dijck">Diemer Van Dijck</name><affiliation wicri:level="1"><nlm:affiliation>Corilus Health IT Center, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Corilus Health IT Center, Ghent</wicri:regionArea><wicri:noRegion>Ghent</wicri:noRegion></affiliation></author><author><name sortKey="Bean, Dan" sort="Bean, Dan" uniqKey="Bean D" first="Dan" last="Bean">Dan Bean</name><affiliation wicri:level="3"><nlm:affiliation>Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Fedson, David" sort="Fedson, David" uniqKey="Fedson D" first="David" last="Fedson">David Fedson</name><affiliation wicri:level="1"><nlm:affiliation>57, chemin du Lavoir, Sergy Haut, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>57, chemin du Lavoir, Sergy Haut</wicri:regionArea><wicri:noRegion>Sergy Haut</wicri:noRegion><wicri:noRegion>Sergy Haut</wicri:noRegion></affiliation></author><author><name sortKey="De Spiegeleer, Bart" sort="De Spiegeleer, Bart" uniqKey="De Spiegeleer B" first="Bart" last="De Spiegeleer">Bart De Spiegeleer</name><affiliation wicri:level="4"><nlm:affiliation>Drug Quality and Registration Group, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. Electronic address: bart.despiegeleer@ugent.be.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Drug Quality and Registration Group, Faculty of Pharmaceutical Sciences, Ghent University, Ghent</wicri:regionArea><orgName type="university">Université de Gand</orgName><placeName><settlement type="city">Gand</settlement><region>Région flamande</region><region type="district" nuts="2">Province de Flandre-Orientale</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32674818</idno><idno type="pmid">32674818</idno><idno type="doi">10.1016/j.jamda.2020.06.018</idno><idno type="pmc">PMC7294267</idno><idno type="wicri:Area/Main/Corpus">000943</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000943</idno><idno type="wicri:Area/Main/Curation">000943</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000943</idno><idno type="wicri:Area/Main/Exploration">000943</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents.</title><author><name sortKey="De Spiegeleer, Anton" sort="De Spiegeleer, Anton" uniqKey="De Spiegeleer A" first="Anton" last="De Spiegeleer">Anton De Spiegeleer</name><affiliation wicri:level="4"><nlm:affiliation>Drug Quality and Registration Group, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium; Department of Geriatrics, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB-Center for Inflammation Research, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Drug Quality and Registration Group, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium; Department of Geriatrics, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB-Center for Inflammation Research, Ghent</wicri:regionArea><orgName type="university">Université de Gand</orgName><placeName><settlement type="city">Gand</settlement><region>Région flamande</region><region type="district" nuts="2">Province de Flandre-Orientale</region></placeName></affiliation></author><author><name sortKey="Bronselaer, Antoon" sort="Bronselaer, Antoon" uniqKey="Bronselaer A" first="Antoon" last="Bronselaer">Antoon Bronselaer</name><affiliation wicri:level="4"><nlm:affiliation>DDCM Laboratory, Department of Telecommunications and Information Processing, Faculty of Engineering and Architecture, Ghent University, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>DDCM Laboratory, Department of Telecommunications and Information Processing, Faculty of Engineering and Architecture, Ghent University, Ghent</wicri:regionArea><orgName type="university">Université de Gand</orgName><placeName><settlement type="city">Gand</settlement><region>Région flamande</region><region type="district" nuts="2">Province de Flandre-Orientale</region></placeName></affiliation></author><author><name sortKey="Teo, James T" sort="Teo, James T" uniqKey="Teo J" first="James T" last="Teo">James T. Teo</name><affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Byttebier, Geert" sort="Byttebier, Geert" uniqKey="Byttebier G" first="Geert" last="Byttebier">Geert Byttebier</name><affiliation wicri:level="1"><nlm:affiliation>Bioconstat BV, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Bioconstat BV, Ghent</wicri:regionArea><wicri:noRegion>Ghent</wicri:noRegion></affiliation></author><author><name sortKey="De Tre, Guy" sort="De Tre, Guy" uniqKey="De Tre G" first="Guy" last="De Tré">Guy De Tré</name><affiliation wicri:level="4"><nlm:affiliation>DDCM Laboratory, Department of Telecommunications and Information Processing, Faculty of Engineering and Architecture, Ghent University, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>DDCM Laboratory, Department of Telecommunications and Information Processing, Faculty of Engineering and Architecture, Ghent University, Ghent</wicri:regionArea><orgName type="university">Université de Gand</orgName><placeName><settlement type="city">Gand</settlement><region>Région flamande</region><region type="district" nuts="2">Province de Flandre-Orientale</region></placeName></affiliation></author><author><name sortKey="Belmans, Luc" sort="Belmans, Luc" uniqKey="Belmans L" first="Luc" last="Belmans">Luc Belmans</name><affiliation wicri:level="1"><nlm:affiliation>Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent</wicri:regionArea><wicri:noRegion>Ghent</wicri:noRegion></affiliation></author><author><name sortKey="Dobson, Richard" sort="Dobson, Richard" uniqKey="Dobson R" first="Richard" last="Dobson">Richard Dobson</name><affiliation wicri:level="3"><nlm:affiliation>Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Wynendaele, Evelien" sort="Wynendaele, Evelien" uniqKey="Wynendaele E" first="Evelien" last="Wynendaele">Evelien Wynendaele</name><affiliation wicri:level="4"><nlm:affiliation>Drug Quality and Registration Group, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Drug Quality and Registration Group, Faculty of Pharmaceutical Sciences, Ghent University, Ghent</wicri:regionArea><orgName type="university">Université de Gand</orgName><placeName><settlement type="city">Gand</settlement><region>Région flamande</region><region type="district" nuts="2">Province de Flandre-Orientale</region></placeName></affiliation></author><author><name sortKey="Van De Wiele, Christophe" sort="Van De Wiele, Christophe" uniqKey="Van De Wiele C" first="Christophe" last="Van De Wiele">Christophe Van De Wiele</name><affiliation wicri:level="1"><nlm:affiliation>Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent</wicri:regionArea><wicri:noRegion>Ghent</wicri:noRegion></affiliation></author><author><name sortKey="Vandaele, Filip" sort="Vandaele, Filip" uniqKey="Vandaele F" first="Filip" last="Vandaele">Filip Vandaele</name><affiliation wicri:level="1"><nlm:affiliation>VZW Zorg-Saam Zusters Kindsheid Jesu, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>VZW Zorg-Saam Zusters Kindsheid Jesu, Ghent</wicri:regionArea><wicri:noRegion>Ghent</wicri:noRegion></affiliation></author><author><name sortKey="Van Dijck, Diemer" sort="Van Dijck, Diemer" uniqKey="Van Dijck D" first="Diemer" last="Van Dijck">Diemer Van Dijck</name><affiliation wicri:level="1"><nlm:affiliation>Corilus Health IT Center, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Corilus Health IT Center, Ghent</wicri:regionArea><wicri:noRegion>Ghent</wicri:noRegion></affiliation></author><author><name sortKey="Bean, Dan" sort="Bean, Dan" uniqKey="Bean D" first="Dan" last="Bean">Dan Bean</name><affiliation wicri:level="3"><nlm:affiliation>Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Fedson, David" sort="Fedson, David" uniqKey="Fedson D" first="David" last="Fedson">David Fedson</name><affiliation wicri:level="1"><nlm:affiliation>57, chemin du Lavoir, Sergy Haut, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>57, chemin du Lavoir, Sergy Haut</wicri:regionArea><wicri:noRegion>Sergy Haut</wicri:noRegion><wicri:noRegion>Sergy Haut</wicri:noRegion></affiliation></author><author><name sortKey="De Spiegeleer, Bart" sort="De Spiegeleer, Bart" uniqKey="De Spiegeleer B" first="Bart" last="De Spiegeleer">Bart De Spiegeleer</name><affiliation wicri:level="4"><nlm:affiliation>Drug Quality and Registration Group, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. Electronic address: bart.despiegeleer@ugent.be.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Drug Quality and Registration Group, Faculty of Pharmaceutical Sciences, Ghent University, Ghent</wicri:regionArea><orgName type="university">Université de Gand</orgName><placeName><settlement type="city">Gand</settlement><region>Région flamande</region><region type="district" nuts="2">Province de Flandre-Orientale</region></placeName></affiliation></author></analytic><series><title level="j">Journal of the American Medical Directors Association</title><idno type="eISSN">1538-9375</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Angiotensin Receptor Antagonists (administration & dosage)</term><term>Angiotensin-Converting Enzyme Inhibitors (administration & dosage)</term><term>Belgium (epidemiology)</term><term>Cause of Death (MeSH)</term><term>Cohort Studies (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Female (MeSH)</term><term>Geriatric Assessment (MeSH)</term><term>Homes for the Aged (statistics & numerical data)</term><term>Humans (MeSH)</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (administration & dosage)</term><term>Logistic Models (MeSH)</term><term>Male (MeSH)</term><term>Nursing Homes (statistics & numerical data)</term><term>Odds Ratio (MeSH)</term><term>Pandemics (statistics & numerical data)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (epidemiology)</term><term>Retrospective Studies (MeSH)</term><term>Risk Assessment (MeSH)</term><term>Severity of Illness Index (MeSH)</term><term>Survival Rate (MeSH)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antagonistes des récepteurs aux angiotensines (administration et posologie)</term><term>Appréciation des risques (MeSH)</term><term>Belgique (épidémiologie)</term><term>Cause de décès (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Indice de gravité de la maladie (MeSH)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (épidémiologie)</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (administration et posologie)</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (administration et posologie)</term><term>Maisons de repos (statistiques et données numériques)</term><term>Maisons de retraite médicalisées (statistiques et données numériques)</term><term>Modèles logistiques (MeSH)</term><term>Mâle (MeSH)</term><term>Odds ratio (MeSH)</term><term>Pandémies (statistiques et données numériques)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (épidémiologie)</term><term>Résultat thérapeutique (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Taux de survie (MeSH)</term><term>Études de cohortes (MeSH)</term><term>Études rétrospectives (MeSH)</term><term>Évaluation gériatrique (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Angiotensin Receptor Antagonists</term><term>Angiotensin-Converting Enzyme Inhibitors</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Belgium</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antagonistes des récepteurs aux angiotensines</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Homes for the Aged</term><term>Nursing Homes</term><term>Pandemics</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Maisons de repos</term><term>Maisons de retraite médicalisées</term><term>Pandémies</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Belgique</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Cause of Death</term><term>Cohort Studies</term><term>Female</term><term>Geriatric Assessment</term><term>Humans</term><term>Logistic Models</term><term>Male</term><term>Odds Ratio</term><term>Retrospective Studies</term><term>Risk Assessment</term><term>Severity of Illness Index</term><term>Survival Rate</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Appréciation des risques</term><term>Cause de décès</term><term>Femelle</term><term>Humains</term><term>Indice de gravité de la maladie</term><term>Modèles logistiques</term><term>Mâle</term><term>Odds ratio</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Taux de survie</term><term>Études de cohortes</term><term>Études rétrospectives</term><term>Évaluation gériatrique</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Belgique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>Angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARBs), and HMG-CoA reductase inhibitors ("statins") have been hypothesized to affect COVID-19 severity. However, up to now, no studies investigating this association have been conducted in the most vulnerable and affected population groups (ie, older adults residing in nursing homes). The objective of this study was to explore the association of ACEi/ARB and/or statins with clinical manifestations in COVID-19-infected older adults residing in nursing homes.</p></div><div type="abstract" xml:lang="en"><p><b>DESIGN</b></p><p>We undertook a retrospective multicenter cohort study to analyze the association between ACEi/ARB and/or statin use with clinical outcome of COVID-19. The outcomes were (1) serious COVID-19 defined as long-stay hospital admission or death within 14 days of disease onset, and (2) asymptomatic (ie, no disease symptoms in the whole study period while still being diagnosed by polymerase chain reaction).</p></div><div type="abstract" xml:lang="en"><p><b>SETTING AND PARTICIPANTS</b></p><p>A total of 154 COVID-19-positive subjects were identified, residing in 1 of 2 Belgian nursing homes that experienced similar COVID-19 outbreaks.</p></div><div type="abstract" xml:lang="en"><p><b>MEASURES</b></p><p>Logistic regression models were applied with age, sex, functional status, diabetes, and hypertension as covariates.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>We found a statistically significant association between statin intake and the absence of symptoms during COVID-19 (odds ratio [OR] 2.91; confidence interval [CI] 1.27-6.71), which remained statistically significant after adjusting for covariates (OR 2.65; CI 1.13-6.68). Although the effects of statin intake on serious clinical outcome were in the same beneficial direction, these were not statistically significant (OR 0.75; CI 0.24-1.87). There was also no statistically significant association between ACEi/ARB and asymptomatic status (OR 2.72; CI 0.59-25.1) or serious clinical outcome (OR 0.48; CI 0.10-1.97).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS AND IMPLICATIONS</b></p><p>Our data indicate that statin intake in older, frail adults could be associated with a considerable beneficial effect on COVID-19 clinical symptoms. The role of statins and renin-angiotensin system drugs needs to be further explored in larger observational studies as well as randomized clinical trials.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32674818</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-9375</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of the American Medical Directors Association</Title><ISOAbbreviation>J Am Med Dir Assoc</ISOAbbreviation></Journal><ArticleTitle>The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents.</ArticleTitle><Pagination><MedlinePgn>909-914.e2</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1525-8610(20)30524-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jamda.2020.06.018</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARBs), and HMG-CoA reductase inhibitors ("statins") have been hypothesized to affect COVID-19 severity. However, up to now, no studies investigating this association have been conducted in the most vulnerable and affected population groups (ie, older adults residing in nursing homes). The objective of this study was to explore the association of ACEi/ARB and/or statins with clinical manifestations in COVID-19-infected older adults residing in nursing homes.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">We undertook a retrospective multicenter cohort study to analyze the association between ACEi/ARB and/or statin use with clinical outcome of COVID-19. The outcomes were (1) serious COVID-19 defined as long-stay hospital admission or death within 14 days of disease onset, and (2) asymptomatic (ie, no disease symptoms in the whole study period while still being diagnosed by polymerase chain reaction).</AbstractText><AbstractText Label="SETTING AND PARTICIPANTS" NlmCategory="METHODS">A total of 154 COVID-19-positive subjects were identified, residing in 1 of 2 Belgian nursing homes that experienced similar COVID-19 outbreaks.</AbstractText><AbstractText Label="MEASURES" NlmCategory="METHODS">Logistic regression models were applied with age, sex, functional status, diabetes, and hypertension as covariates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found a statistically significant association between statin intake and the absence of symptoms during COVID-19 (odds ratio [OR] 2.91; confidence interval [CI] 1.27-6.71), which remained statistically significant after adjusting for covariates (OR 2.65; CI 1.13-6.68). Although the effects of statin intake on serious clinical outcome were in the same beneficial direction, these were not statistically significant (OR 0.75; CI 0.24-1.87). There was also no statistically significant association between ACEi/ARB and asymptomatic status (OR 2.72; CI 0.59-25.1) or serious clinical outcome (OR 0.48; CI 0.10-1.97).</AbstractText><AbstractText Label="CONCLUSIONS AND IMPLICATIONS" NlmCategory="CONCLUSIONS">Our data indicate that statin intake in older, frail adults could be associated with a considerable beneficial effect on COVID-19 clinical symptoms. The role of statins and renin-angiotensin system drugs needs to be further explored in larger observational studies as well as randomized clinical trials.</AbstractText><CopyrightInformation>Copyright © 2020 AMDA – The Society for Post-Acute and Long-Term Care Medicine. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Spiegeleer</LastName><ForeName>Anton</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Drug Quality and Registration Group, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium; Department of Geriatrics, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB-Center for Inflammation Research, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bronselaer</LastName><ForeName>Antoon</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>DDCM Laboratory, Department of Telecommunications and Information Processing, Faculty of Engineering and Architecture, Ghent University, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teo</LastName><ForeName>James T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byttebier</LastName><ForeName>Geert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Bioconstat BV, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Tré</LastName><ForeName>Guy</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>DDCM Laboratory, Department of Telecommunications and Information Processing, Faculty of Engineering and Architecture, Ghent University, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belmans</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dobson</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wynendaele</LastName><ForeName>Evelien</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Drug Quality and Registration Group, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van De Wiele</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandaele</LastName><ForeName>Filip</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>VZW Zorg-Saam Zusters Kindsheid Jesu, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Dijck</LastName><ForeName>Diemer</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Corilus Health IT Center, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bean</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fedson</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>57, chemin du Lavoir, Sergy Haut, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Spiegeleer</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Drug Quality and Registration Group, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. Electronic address: bart.despiegeleer@ugent.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Med Dir Assoc</MedlineTA><NlmUniqueID>100893243</NlmUniqueID><ISSNLinking>1525-8610</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Pharmacol Res. 2020 Sep;159:105033</RefSource><PMID Version="1">32562814</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001530" MajorTopicYN="N" Type="Geographic">Belgium</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006707" MajorTopicYN="N">Homes for the Aged</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Angiotensin-converting enzyme inhibitors</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">angiotensin II receptor blockers</Keyword><Keyword MajorTopicYN="N">nursing home residents</Keyword><Keyword MajorTopicYN="N">statins</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>06</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32674818</ArticleId><ArticleId IdType="pii">S1525-8610(20)30524-7</ArticleId><ArticleId IdType="doi">10.1016/j.jamda.2020.06.018</ArticleId><ArticleId IdType="pmc">PMC7294267</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Perit Dial Int. 2009 Sep-Oct;29(5):554-61</Citation><ArticleIdList><ArticleId IdType="pubmed">19776050</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation><ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Transl Med. 2016 Nov;4(21):421</Citation><ArticleIdList><ArticleId IdType="pubmed">27942512</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Microbes Infect. 2020 Dec;9(1):757-760</Citation><ArticleIdList><ArticleId IdType="pubmed">32228222</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol Lung Cell Mol Physiol. 2005 Jun;288(6):L1026-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15665042</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 May 21;382(21):2005-2011</Citation><ArticleIdList><ArticleId IdType="pubmed">32220208</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Genet. 2014 Jun 19;5:187</Citation><ArticleIdList><ArticleId IdType="pubmed">24995013</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2005 Jul 7;436(7047):112-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16001071</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2020 Jul;20(7):389-391</Citation><ArticleIdList><ArticleId IdType="pubmed">32439870</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thromb Thrombolysis. 2020 Apr 3;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32246317</ArticleId></ArticleIdList></Reference><Reference><Citation>Autoimmun Rev. 2020 Jun;19(6):102537</Citation><ArticleIdList><ArticleId IdType="pubmed">32251717</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Crit Care Med. 2013 Nov;14(9):e438-41</Citation><ArticleIdList><ArticleId IdType="pubmed">24226567</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Mar 23;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32203977</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2020 Jul 7;76(1):122-124</Citation><ArticleIdList><ArticleId IdType="pubmed">32387623</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Med Sci. 2020 Apr 25;16(3):490-496</Citation><ArticleIdList><ArticleId IdType="pubmed">32399094</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thromb Haemost. 2020 Apr;18(4):844-847</Citation><ArticleIdList><ArticleId IdType="pubmed">32073213</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Invest. 2019 Aug;49(8):e13130</Citation><ArticleIdList><ArticleId IdType="pubmed">31112290</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Heart Fail. 2020 Jun 2;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32485082</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2012 Dec;55(11):1466-73</Citation><ArticleIdList><ArticleId IdType="pubmed">22918991</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pathol. 2011 Dec;225(4):618-27</Citation><ArticleIdList><ArticleId IdType="pubmed">22009550</ArticleId></ArticleIdList></Reference><Reference><Citation>mBio. 2020 Mar 20;11(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">32198163</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2020 Apr 1;130(4):1545-1548</Citation><ArticleIdList><ArticleId IdType="pubmed">32167489</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2005 Aug;11(8):875-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16007097</ArticleId></ArticleIdList></Reference><Reference><Citation>J Crit Care. 2020 Jun;57:279-283</Citation><ArticleIdList><ArticleId IdType="pubmed">32173110</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Res Clin Pract. 2018 Jan;135:88-92</Citation><ArticleIdList><ArticleId IdType="pubmed">29155121</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jun 11;382(24):2327-2336</Citation><ArticleIdList><ArticleId IdType="pubmed">32275812</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2020 Apr 29;369:m1727</Citation><ArticleIdList><ArticleId IdType="pubmed">32350004</ArticleId></ArticleIdList></Reference><Reference><Citation>Circ Res. 2020 Jun 5;126(12):1671-1681</Citation><ArticleIdList><ArticleId IdType="pubmed">32302265</ArticleId></ArticleIdList></Reference><Reference><Citation>Ear Nose Throat J. 2020 Apr 13;:145561320920762</Citation><ArticleIdList><ArticleId IdType="pubmed">32283980</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Belgique</li><li>France</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li><li>Province de Flandre-Orientale</li><li>Région flamande</li></region><settlement><li>Gand</li><li>Londres</li></settlement><orgName><li>Université de Gand</li></orgName></list><tree><country name="Belgique"><region name="Région flamande"><name sortKey="De Spiegeleer, Anton" sort="De Spiegeleer, Anton" uniqKey="De Spiegeleer A" first="Anton" last="De Spiegeleer">Anton De Spiegeleer</name></region><name sortKey="Belmans, Luc" sort="Belmans, Luc" uniqKey="Belmans L" first="Luc" last="Belmans">Luc Belmans</name><name sortKey="Bronselaer, Antoon" sort="Bronselaer, Antoon" uniqKey="Bronselaer A" first="Antoon" last="Bronselaer">Antoon Bronselaer</name><name sortKey="Byttebier, Geert" sort="Byttebier, Geert" uniqKey="Byttebier G" first="Geert" last="Byttebier">Geert Byttebier</name><name sortKey="De Spiegeleer, Bart" sort="De Spiegeleer, Bart" uniqKey="De Spiegeleer B" first="Bart" last="De Spiegeleer">Bart De Spiegeleer</name><name sortKey="De Tre, Guy" sort="De Tre, Guy" uniqKey="De Tre G" first="Guy" last="De Tré">Guy De Tré</name><name sortKey="Van De Wiele, Christophe" sort="Van De Wiele, Christophe" uniqKey="Van De Wiele C" first="Christophe" last="Van De Wiele">Christophe Van De Wiele</name><name sortKey="Van Dijck, Diemer" sort="Van Dijck, Diemer" uniqKey="Van Dijck D" first="Diemer" last="Van Dijck">Diemer Van Dijck</name><name sortKey="Vandaele, Filip" sort="Vandaele, Filip" uniqKey="Vandaele F" first="Filip" last="Vandaele">Filip Vandaele</name><name sortKey="Wynendaele, Evelien" sort="Wynendaele, Evelien" uniqKey="Wynendaele E" first="Evelien" last="Wynendaele">Evelien Wynendaele</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Teo, James T" sort="Teo, James T" uniqKey="Teo J" first="James T" last="Teo">James T. Teo</name></region><name sortKey="Bean, Dan" sort="Bean, Dan" uniqKey="Bean D" first="Dan" last="Bean">Dan Bean</name><name sortKey="Dobson, Richard" sort="Dobson, Richard" uniqKey="Dobson R" first="Richard" last="Dobson">Richard Dobson</name></country><country name="France"><noRegion><name sortKey="Fedson, David" sort="Fedson, David" uniqKey="Fedson D" first="David" last="Fedson">David Fedson</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000474 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000474 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32674818
|texte= The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32674818" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |